Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate.
Yurkevicz A, Liu Y, Katz S, Glazer P. Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate. Molecular Cancer Therapeutics 2024, 24: 105-117. PMID: 39382073, PMCID: PMC11695185, DOI: 10.1158/1535-7163.mct-23-0809.Peer-Reviewed Original ResearchMajor histocompatibility complexT cellsTumor cellsTreatment of tumor-bearing miceMajor histocompatibility complex class I pathwaySuppression of tumor growthTumor cells in vivoT-cell therapySyngeneic tumor modelsTumor-specific antigensTumor-bearing miceMelanoma tumor cellsT cell activationHealthy tissueTarget tumor cellsIn vivoIn vitroMicroenvironment of tumorsUnique delivery platformsClass I pathwayCell-based therapiesTargeted cancer therapyCells in vivoAntigen processing pathwayAcidic microenvironment of tumorsFinding Your CAR The Road Ahead for Engineered T Cells
Chen P, Raghunandan R, Morrow J, Katz S. Finding Your CAR The Road Ahead for Engineered T Cells. American Journal Of Pathology 2024, 194: 1409-1423. PMID: 38697513, PMCID: PMC11284763, DOI: 10.1016/j.ajpath.2024.04.002.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T cellsAdoptive cellular therapyEngineered T cellsT cellsCellular therapyTumor cellsInfusion of CAR T cellsChimeric antigen receptor T cellsCAR-T cell cytotoxicityCAR-T cell persistenceCAR-T cell therapyT cell persistenceT-cell therapyT cell cytotoxicityTarget tumor antigensCytokine release syndromePathology laboratoryEvaluate side effectsTarget specific antigensTarget antigen identificationTransformative immunotherapyTumor antigensAntigen lossTumor microenvironment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply